Abstract
BACKGROUND No therapies for targeting KRAS mutations in cancer have been approved. The KRAS p.G12C mutation occurs in 13% of non-small-cell lung cance......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
